1. Home
  2. AQST vs YDES Comparison

AQST vs YDES Comparison

Compare AQST & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aquestive Therapeutics Inc.

AQST

Aquestive Therapeutics Inc.

N/A

Current Price

$4.68

Market Cap

529.4M

Sector

Health Care

ML Signal

N/A

YDES

YD Bio Limited Ordinary Shares

N/A

Current Price

$4.71

Market Cap

543.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AQST
YDES
Founded
2004
2013
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.4M
543.0M
IPO Year
2007
2024

Fundamental Metrics

Financial Performance
Metric
AQST
YDES
Price
$4.68
$4.71
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
3.6M
42.4K
Earning Date
05-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,430,000.00
N/A
Revenue This Year
$10.08
N/A
Revenue Next Year
$49.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.77
N/A
52 Week Low
$2.94
$1.70
52 Week High
$7.55
$25.00

Technical Indicators

Market Signals
Indicator
AQST
YDES
Relative Strength Index (RSI) 66.99 78.79
Support Level $4.03 $4.73
Resistance Level $5.10 $5.36
Average True Range (ATR) 0.25 0.48
MACD 0.08 0.28
Stochastic Oscillator 94.98 92.58

Price Performance

Historical Comparison
AQST
YDES

About AQST Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Share on Social Networks: